All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or Myeloma crowd.
Did you miss ASH 2020? The Multiple Myeloma Hub attended the virtual 62nd ASH Annual Meeting & Exposition, December, 5–8 2020, and has developed two resources in collaboration with our Steering Committee on the abstracts presented regarding multiple myeloma (MM) that could impact your clinical practice in the near future.
In the first downloadable resource, 'practice-changing abstracts', you will find comments from the Multiple Myeloma Hub Steering Committee members about the role of autologous stem cell transplant in the era of novel agents, and the latest updates on new combinations and therapy-sequencing strategies to achieve deeper and more durable responses.
ASH 2020 | Practice-changing abstracts in multiple myeloma
If you would like to view the practice-changing abstracts from ASH 2020 and the expert opinions from our Steering Committee, please download the resource belowDownload here
Our second resource, 'breakthrough abstracts', covers the most exciting news about monitoring MM with less-invasive techniques and promising alternative targets to treat refractory disease. Discover underlying resistance mechanisms that could help to early identify relapse or fundament new drug combinations. Find here, the initial results obtained with novel targeted agents and the latest about BCMA-directed immunotherapies (bispecific antibodies and CAR T-cells) in clinical development.
ASH 2020 | Breakthrough abstracts in multiple myeloma
If you would like to view the breakthrough abstracts from ASH 2020 and the expert opinions from our Steering Committee, please download the resource belowDownload here
ASH 2019 | Practice-changing abstracts in multiple myeloma
The Multiple Myeloma Hub has developed a downloadable resource, which provides an update on the practice-changing abstracts in multiple myeloma from ASH 2019 in preparation for ASH 2020.
Relapsed/refractory multiple myeloma: what can we target next?
Nicola Giuliani, University of Parma, Parma, IT, and colleagues published a review article in the Expert Review of Hematology, which addressed current and novel targets for treating...
Subscribe to get the best content related to multiple myeloma delivered to your inbox